The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Zemlyanoy A.B.

Department of Surgery, Institute of Advanced Medical Training, Moscow State University of Food Production, Moscow, Russia

Local hemostatic agent — fluid active hemostatic matrix

Authors:

Zemlyanoy A.B.

More about the authors

Journal: Pirogov Russian Journal of Surgery. 2019;(5): 104‑115

DOI: 10.17116/hirurgia2019051104

Read: 3951 times

Download PDF (RU)
Contact the author
Table of contents

LOCAL HEMOSTATIC AGENT — FLUID ACTIVE HEMOSTATIC MATRIX
LOCAL HEMOSTATIC AGENT — FLUID ACTIVE HEMOSTATIC MATRIX

To cite this article:

Zemlyanoy AB. Local hemostatic agent — fluid active hemostatic matrix. Pirogov Russian Journal of Surgery. 2019;(5):104‑115. (In Russ.)
https://doi.org/10.17116/hirurgia2019051104

Подписка 2025-2 (Pirogov Russian Journal of Surgery)
МСФ на ЯМ
Использование инфографики авторами научных работ
Mediasphera_Net
Close metadata

Uncontrolled surgical bleeding can have significant clinical and economic consequences including advanced medical expenses and impairment of the outcomes. Effective and safe local hemostatic agents based on a fluid active hemostatic matrix are reviewed in the article. The use of this agent is followed by reduced hospital-stay, number of redo interventions for bleeding, reduced time of surgery, intra- and postoperative complication rate and high economic efficiency.

Keywords:

bleeding
blood loss
transfusion
complications
hemostasis
local hemostatic agents
cost
expenses
economic effect

Authors:

Zemlyanoy A.B.

Department of Surgery, Institute of Advanced Medical Training, Moscow State University of Food Production, Moscow, Russia

List of references:

  1. Stokes ME, Ye X, Shah M, et al. Impact of bleeding-related complications and/or blood product transfusions on hospital costs in inpatient surgical patients. BMC Health Services Research. 2011;11:135.
  2. Blumberg N, Heal JM. Immunomodulation by blood transfusion: an evolving scientific and clinical challenge. Am J Med. 1996;101:299-308.
  3. Koch CG, Khandwala F, Li L, et al. Persistent effect of red cell transfusion on health-related quality of life after cardiac surgery. Ann Thorac Surg. 2006;82(1):13-20.
  4. Shander A, Hofmann A, Ozawa S, et al. Activity-based costs of blood transfusions in surgical patients at four hospitals. Transfusion. 2010;50:753-765.
  5. Krishna S. Vyas, Sibu P, Saha MD, MBA Comparison of hemostatic agents used in vascular surgery. MHS, MS-III2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4390172/
  6. Spotnitz WD. Hemostats, sealants, and adhesives: a practical guide for the surgeon. Am Surg. 2012 Dec;78(12):1305-1321.
  7. Minato N, Katayama Y, Yunoki J, et al. Hemostatic effectiveness of a new application method for fibrin glue, the rub-and-spray method, in emergency aortic surgery for acute aortic dissection. Ann Thorac Cardiovasc Surg. 2009;15:265-271.
  8. Oz MC, et al. Floseal Matrix: New Generation Topical Hemostatic Sealant. J Card Surg. 2003;18:486-493.
  9. Renkens KL, Payner TD, Leipzig TJ, et al. A multicenter, prospective, randomized trial evaluating a new hemostatic agent for spinal surgery. Spine. 2001;26(15):1645-1650.
  10. Gazzeri R, et al. Minimal craniotomy and matrix hemostatic sealant for the treatment of spontaneous supratentorial intracerebral hemorrhage. J Neurosurg. 2009;110(5):939-942.
  11. Ellegala DB, et al. Use of FloSeal hemostatic sealant in transsphenoidal pituitary surgery: technical note. Neurosurgery. 2002;51:513-516.
  12. Nasso G, Piancone F, Bonifazi R, et al. Prospective, randomized clinical trial of the FloSeal matrix sealant in cardiac surgery. Ann Thorac Surg. 2009;88(5):1520-1526.
  13. Oz MC, Cosgrove DM III, Badduke BR, et al. Controlled clinical trial of a novel hemostatic agent in cardiac surgery. Ann Thorac Surg. 2000;69:1376-1382.
  14. Weaver FA, et al. Gelatin-thrombin-based hemostatic sealant for intraoperative bleeding in vascular surgery. Ann Vasc Surg. 2002;16(3):286-293.
  15. Tackett SM, et al. Real-world outcomes of hemostatic matrices in cardiac surgery. J Cardiothor Vasc Anesth. 2014;28:1558-1565.
  16. Krishnan S, et al. Choice of hemostatic agent and hospital length of stay in cardiovascular surgery. Semin Cardiothorac Vasc Anesth. 2009;13(4):225-230.
  17. D’Andrilli A, et al. Evaluation of the efficacy of a haemostatic matrix for control of intraoperative and postoperative bleeding in major lung surgery: a prospective, randomized study. Eur J Cardio-Thorac Surg. 2015;48:679-683.
  18. Renkens KL, Payner TD, Leipzig TJ, et al. A multicenter, prospective, randomized trial evaluating a new hemostatic agent for spinal surgery. Spine. 2001;26(15):1645-1650.
  19. Price JS, Tackett S, Patel V. Observational evaluation of outcomes and resource utilization from hemostatic matrices in spine surgery. J Med Econ. 2015;1-10.
  20. Li QY, et al. Efficacy of a topical gelatin-thrombin matrix sealant in reducing postoperative drainage following anterior cervical discectomy and fusion. Asian Spine J. 2015;9(6):909-915.
  21. Gazzeri R, et al. Minimal craniotomy and matrix hemostatic sealant for the treatment of spontaneous supratentorial intracerebral hemorrhage. J Neurosurg. 2009;110(5):939-942.
  22. Gazzeri R, et al. Hemostatic matrix sealant in neurosurgery: a clinical and imaging study. Acta Neurochir (Wien). 2011;153:148-154, discussion 155.
  23. Ellegala DB, et al. Use of FloSeal hemostatic sealant in transsphenoidal pituitary surgery: technical note. Neurosurgery. 2002;51:513-516.
  24. Fiss I, et al. Use of gelatin-thrombin matrix hemostatic sealant in cranial neurosurgery. Neurol Med Chir (Tokyo). 2007;47:462-467.
  25. Stacey MJ, et al. Use of FloSeal matrix hemostatic agent in partial splenectomy after penetrating trauma. J Trauma. 2008;64(2):507-508.
  26. Izzo F, et al. Efficacy of a haemostatic matrix for the management of bleeding in patients undergoing liver resection: results from 237 cases. Curr Med Res Opin. 2008;24:1011-1015.
  27. Sartelli M, et al. Use of Floseal hemostatic matrix for control of hemostasis during laparoscopic cholecystectomy for acute cholecystitis: a multicenter historical control group comparison (The GLA study gelatin matrix for acute cholecystitis). J Laparoendosc Adv Surg Tech. 2014;24:837-841.
  28. Stacey MJ, et al. Use of FloSeal matrix hemostatic agent in partial splenectomy after penetrating trauma. J Trauma. 2008;64(2):507-508.
  29. Testini M, Marzaioli R, Lissidini G, et al. The effectiveness of FloSeal® matrix hemostatic agent in thyroid surgery: a prospective, randomized, control study. Langenbecks Arch Surg. 2009;394(5):837-842.
  30. Raga F, et al. Reducing blood loss at myomectomy with use of a gelatin-thrombin matrix hemostatic sealant. Fertil Steril. 2009;92:356-360.
  31. Moriarty KT, Premila S, Bulmer PJ. Use of FloSeal™ haemostatic gel in massive obstetric haemorrhage: a case report. BJOG. 2008;115:793-795.
  32. Wohlmuth CT., Dela Merced J. Gelatin-thrombin hemostatic matrix in the management of placental site postpartum hemorrhage. J Reprod Med. 2011 May-Jun;56(5-6):271-273.
  33. Law LW, et al. Use of Hemostatic Gel in Postpartum Hemorrhage Due to Placenta Previa. Obstet Gynecol. 2010 Aug;116 Suppl 2:528-530.
  34. Angioli R, et al. Feasibility of the use of novel matrix hemostatic sealant (FloSeal) to achieve hemostasis during laparoscopic excision of endometrioma. J Minim Invasive Gynecol. 2009;16(2):153-156.
  35. Song T, et al. Additional benefit of hemostatic sealant in preservation of ovarian reserve during laparoscopic ovarian cystectomy: a multi-center, randomized controlled trial. Hum Reprod. 2014 Aug;29(8):1659-1665.
  36. Choi C, et al. Usefulness of hemostatic sealants for minimizing ovarian damage during laparoscopic cystectomy for endometriosis. J Obstet Gynaecol Res. 2018 Mar;44(3):532-539.
  37. Watrowski R, Jäger C, Forster J. A Specific Survival Score for Patients Receiving Local Therapy for Single Brain Metastasis from a Gynecological Malignancy. In Vivo. 2018 July 1;32(4):825-828.
  38. Martorana E, et al. A retrospective analysis of the hemostatic effect of FloSeal in patients undergoing robotic-assisted laparoscopic radical prostatectomy. Urol Intl. 2016;96:274-279.
  39. Nagele U, et al. Introducing a new sealant applicator for easy, safe, and quick closure of a mini-percutaneous nephrolitholapaxy access tract. J Endourol. 2007;21:393-396.
  40. Richter F, et al. Improvement of hemostasis in open and laparascopically performed partial nephrectomy using a gelatin matrix-thrombin tissue sealant (FloSeal). Urology. 2003;61:73-77.
  41. Bak JB, Singh A, Shekarriz B. Use of gelatin matrix thrombin tissue sealant as an effective hemostatic agent during laparoscopic partial nephrectomy. J Urol. 2004;171:780-782.
  42. Gill IS, et al. Improved hemostasis during laparoscopic partial nephrectomy using gelatin matrix thrombin sealant. Urology. 2005;65(3):463-466.
  43. Wille AH, et al. Laparoscopic partial nephrectomy in renal cell cancer–indications, technique, and outcome in 80 patients. European Urology Supplements. 2007;6:635-640.
  44. Pace G, et al. Haemostatics in surgery and our experience in the enucleoresection of renal cell carcinoma. World J Surg Oncol. 2010;8:1-6.
  45. Triaca V, et al. Does thrombin sealant allow nephron-sparing surgery with no renal artery occlusion? A description of technique and intial results. BJU Int. 2005;95(9):1273-1275.
  46. Nasso G, Piancone F, Bonifazi R, et al. Prospective, randomized clinical trial of the FloSeal matrix sealant in cardiac surgery. Ann Thorac Surg. 2009;88(5):1520-1526
  47. Ortler M, Obernauer J, Gabl M, et al. Usefulness of a novel thrombin-based hemostatic agent in lumbar spondylodesis surgery [electronic poster 2821].
  48. Bedi AD, Toms SA, Dehdashti AR. Use of hemostatic matrix for hemostasis of the cavernous sinus during endoscopic endonasal pituitary and suprasellar tumor surgery. Otolaryngology. 2009; vol. 140:2:262-263.
  49. Comadoll JL, Comadoll S, Hutchcraft A, et al. Decreased blood loss in total knee arthroplasty patients by using a novel gelatin/thrombin hemostatic agent [abstract]. Presented at American Academy of Neurological and Orthopaedic Surgeons 35th Annual Scientific Meeting, Portland OR. 2011 10-11 June.
  50. Tackett SM, et al. Real-world outcomes of hemostatic matrices in cardiac surgery. J Cardiothor Vasc Anesth. 2014;28:1558-1565.
  51. Price JS, Tackett S, Patel V. Observational evaluation of outcomes and resource utilization from hemostatic matrices in spine surgery. J Med Econ. 2015;1-10.
  52. Nagele U, et al. Closing the tract of mini-percutaneous nephrolithotomy with gelatine matrix hemostatic sealant can replace nephrostomy tube placement. Urology. 2006;68:489-494.
  53. Greco DP, et al. Stapled hemorroidopexy: day surgery or one day surgery? Surg Oncol. 2007;16:S173-S175.
  54. Sartelli M, et al. Use of Floseal hemostatic matrix for control of hemostasis during laparoscopic cholecystectomy for acute cholecystitis: a multicenter historical control group comparison (The GLA study gelatin matrix for acute cholecystitis). J Laparoendosc Adv Surg Tech. 2014;24:837-841.
  55. Cardillo G, et al. Control of major pulmonary artery bleeds with a gelatin matrix-thrombin solution: a retrospective analysis. J Cardiovasc Surg (Torino). 2017 Dec;58(6):904-908.
  56. Tackett SM, et al. Real-world outcomes of hemostatic matrices in cardiac surgery. J Cardiothor Vasc Anesth. 2014;28:1558-1565.
  57. Makhija D, et al. Cost-consequence analysis of different active flowable hemostatic matrices in cardiac surgical procedures. Journal of Medical Economics. 2017. https://doi.org/10.1080/13696998.2017.1284079
  58. Nasso G, Piancone F, Bonifazi R, et al. Prospective, randomized clinical trial of the FloSeal matrix sealant in cardiac surgery. Ann Thorac Surg. 2009;88(5):1520-1526.
  59. Tackett SM, et al. Hospital economic impact from hemostatic matrix usage in cardiac surgery. Journal of Medical Economics. 2014;17(9):670-676.
  60. Joshi M, et al. Use of a flowable haemostat versus an oxidised regenerated cellulose agent in primary elective cardiac surgery: economic impact from a UK healthcare perspective. Journal of Cardiothoracic Surgery. 2017;12:107.
  61. Makhija D, et al. Cost-consequence analysis of two different active flowable hemostatic matrices in spine surgery patients. Journal of Medical Economics. https://doi.org/10.1080/13696998.2017.1292916
  62. Oz MC, Cosgrove DM III, Badduke BR, et al. Controlled clinical trial of a novel hemostatic agent in cardiac surgery. Ann Thorac Surg. 2000;69:1376-1382.
  63. Narayan S, Tucker M, Shander A. An economic model to assess Floseal Hemostatic Matrix versus Gelfoam with bovine thrombin to reduce peri-operative blood loss during cardiovascular procedures. SABM Conference. Hollywood, California. 2007 September 7-9.
  64. Tackett SM, Calcaterra D, Magee G, Lattouf OM. Real-world outcomes of hemostatic matrices in cardiac surgery. J Cardiothor Vasc Anesth. 2014;28:1558-1556.
  65. Renkens KL, Payner TD, Leipzig TJ, et al. A multicenter, prospective, randomized trial evaluating a new hemostatic agent for spinal surgery. Spine. 2001;26(15):1645-1650.
  66. Price JS, Tackett S, Patel V. Observational evaluation of outcomes and resource utilization from hemostatic matrices in spine surgery. J Med Econ. 2015;1-10.
  67. Gazzeri R, Galarza M, Neroni M, Alfieri A, Esposito S. Minimal craniotomy and matrix hemostatic sealant for the treatment of spontaneous supratentorial intracerebral hemorrhage. J Neurosurg. 2009;110(5):939-942.
  68. Testini M, et al. The effectiveness of FloSeal® matrix hemostatic agent in thyroid surgery: a prospective, randomized, control study. Langenbecks Arch Surg. 2009;394(5):837-842.
  69. Tackett SM, Calcaterra D, Magee G, Lattouf OM. Real-world outcomes of hemostatic matrices in cardiac surgery. J Cardiothor Vasc Anesth. 2014;28:1558-1565.
  70. Tackett SM, Calcaterra D, Magee G, Lattouf OM. Real-world outcomes of hemostatic matrices in cardiac surgery. J Cardiothor Vasc Anesth. 2014;28:1558-1565.
  71. Waldert M, et al. FloSeal reduces the incidence of lymphoceles after lymphadenectomies in laparoscopic and robot-assisted extraperitoneal radical prostatectomy. J Endourol. 2011;25:969-973.
  72. Nasso G, Piancone F, Bonifazi R, et al. Prospective, randomized clinical trial of the FloSeal matrix sealant in cardiac surgery. Ann Thorac Surg. 2009;88(5):1520-1526.
  73. Oz MC, Cosgrove DM III, Badduke BR, et al. Controlled clinical trial of a novel hemostatic agent in cardiac surgery. Ann Thorac Surg. 2000;69:1376-1382.
  74. Tackett SM, et al. Hospital economic impact from hemostatic matrix usage in cardiac surgery. J Med Econ. 2014;17:670-676.
  75. Tackett SM, et al. Real-world outcomes of hemostatic matrices in cardiac surgery. J Cardiothor Vasc Anesth. 2014;28:1558-1565.
  76. D’Andrilli A, et al. Evaluation of the efficacy of a haemostatic matrix for control of intraoperative and postoperative bleeding in major lung surgery: a prospective, randomized study. Eur J Cardio-Thorac Surg. 2015;48:679-683.
  77. Shander A, Hofmann A, Ozawa S, et al. Activity-based costs of blood transfusions in surgical patients at four hospitals. Transfusion. 2010;50:753-765.
  78. Narayan S, Stemkowski S, Conner T, et al. A cost comparison of cardiac surgeries by choice of hemostatic agent [abstract]. ISPOR Annual Conference. Toronto (Canada). 2008 3-7 May.
  79. Waldert M, Remzi M, Klatte T, Klingler HC. FLOSEAL reduces the incidence of lymphoceles after lymphadenectomies in laparoscopic and robot-assisted extraperitoneal radical prostatectomy. J Endourol. 2011;25:969-973.
  80. Ramirez MG, et al. Floseal only versus in combination in spine surgery: a comparative, retrospective hospital database evaluation of clinical and healthcare resource outcomes. Hospital Practice. 2018. https://doi.org/10.1080/21548331.2018.1498279
  81. Tackett SM, MHA, MPH, et al. Real World Outcomes of Hemostatic Matrices in Cardiac Surgery. Journal, Cariothoracic and Vascular Anesthesia. 2014 Dec;28(6):1558-1565.
  82. Manuel G. Ramirez, Xiaoli Niu, Josh Epstein,Dongyan Yang. Cost-consequence analysis of a hemostatic matrix alone or in combination for spine surgery patients. Journal of Medical Economics. 2018;21(10):1041-1046. https://doi.org/10.1080/13696998.2018.1513261
  83. Makhija D, Rock M, Ikeme S, et al. Cost-consequence analysis of two different active flowable hemostatic matrices in spine surgery patients. J Med Econ. 2017;20:606-613.
  84. Tackett SM, Sugarman R, Kreuwel HT, et al. Hospital economic impact from hemostatic matrix usage in cardiac surgery. J Med Econ. 2014;17:670-676.
  85. Makhija D, Rock M, Xiong Y, et al. Cost-consequence analysis of different active flowable hemostatic matrices in cardiac surgical procedures. J Med Econ. 2017;20:565-573.
  86. Nasso G, Piancone F, Bonifazi R, Romano V, Visicchio G, Carlo Maria De Filippo, Impiombato B, Fiore F, Bartolomucci F, Alessandrini F, Speziale G. Ann Thorac Surg. 2009;88(5):1520-1526.
  87. Nasso G, Piancone F, Bonifazi R, et al. Prospective, randomized clinical trial of the FloSeal matrix sealant in cardiac surgery. Ann Thorac Surg. 2009;88:1520-1526.
  88. Raga F, Sanz-Cortes M,Bonilla F, et al. Reducing blood loss at myomectomy with use of a gelatin-thrombin matrix hemostatic sealant. Fertil Steril. 2009;92:356-360.
  89. Mozet C, Prettin C, Dietze M, et al. Use of Floseal and effects on wound healing and pain in adults undergoing tonsillectomy: randomized comparison versus electrocautery. Eur Arch Otorhinolaryngology. 2012;269:2247-2254.
  90. Scott M. Tackett Baxter Healthcare Corporation, Westlake Village, CA, USA Rebecca Sugarman Evidera, Lexington, MA, USA; Huub T. C. Kreuwel Baxter Healthcare Corporation, Westlake Village, CA, USA; Piedad Alvarez Evidera, Lexington, MA, USA; Giuseppe Nasso Department of Cardiac Surgery, Anthea Hospital, GVM Care & Research, Bari, Italy, 2005.
  91. Nasso G, Piancone F, Bonifazi R, et al. Prospective, randomized clinical trial of the FloSeal matrix sealant in cardiac surgery. Ann Thorac Surg. 2009;88:1520-1526.
  92. Faivre P, Laplante S, Kreuwel H. Multi European country cost consequence comparison of Floseal Matrix and Surgiflo thrombin in major and severe spine surgeries. Value in Health. 2015;18:A370. PMD146
  93. Makhija D, Rock M, Xiong Y, Epstein JD, Arnold MR, Lattouf OM, Calcaterra D. Cost-consequence analysis of two different active flowable hemostatic matrices in spine surgery patients. Eds. Makhijaa D, Rocka M, Ikemea S, Kuntzea E, Epsteinb JD, Nicholsonb G, Pricec JC, Pateld V. Baxter Healthcare Corporation, Deerfield, IL, USA; Stratevi, Santa Monica, CA, USA, 2017.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.